Table 5 Rates of adverse events, UC-related hospitalisations and colectomies in the study population.

From: Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

Safety

Global (n = 190)

Anti-TNF naïve (n = 105)

Previously treated with an anti-TNF (n = 85)

p

Adverse events

31 (17.1%)

21 (21.4%)

10 (12%)

0.12

Hospitalizations

32 (16.8%)

15 (14.3%)

17 (20%)

0.29

Surgery

11 (5.8%)

4 (3.8%)

7 (8.2%)

0.18

Back to article page